Latest news with #anti-aging
Daily Mail
15-07-2025
- Entertainment
- Daily Mail
Leslie Ash, 65, shows off her youthful face as she opens about doing £4,500 'facelift' that 'made her look ten years younger'
Leslie Ash has opened up about doing a £4,500 non-surgical facelift that made her look 'ten years younger'. The beloved BBC star, 65, showed off the jaw-dropping results of the revolutionary method, which she has been secretly doing for the past eight months. 'My friends think I've had a facelift - but I've definitely not gone under the knife,' the Holby City favourite told candidly as she praised the avant-garde NeoGen treatment. Leslie admitted to being a bit of a 'wuss' when it comes to pain but said the NeoGen treatments were bearable - in a move which comes 23 years after she famously underwent botched lip fillers and inspired the term 'Trout Pout'. On the new treatment, she said: 'It's quite a weird sensation, I was lathered in numbing cream for half an hour before having the treatment. It's non-invasive but you can feel it, you can put up with it though. 'You might be a bit red for a day or two afterwards, like you've had a bit too much sun, but after that it's just amazing, your skin just feels so much tighter and you start to notice your pores closing,' she finished. As she looked at some before and after treatment pictures, she was quick to point out: 'The difference is really noticeable, and what's really blown my mind is my jawline, it's so obvious that it has lifted. 'Also, my eyes look so much better, they were hooded before and now you can see my eyes are completely a different shape. 'Then you come to the texture of my skin, and reduction of my pores, now it looks soft as anything and the colour is uniform, so there are four major things that are demonstrably improved.' The Happy Apple icon was aiming for a natural result rather than resorting to plastic surgery in order to maintain her natural beauty. 'It doesn't look fake or overdone at all. It's just me, but a much better version of me,' Leslie told. 'My skin feels tighter and more plump, and the overall texture and tone is so much better. The actress added proudly: 'I can definitely say I look like I'm in my mid 50s, so yeah, I'm happy with that, ten years younger.' 'Also, my eyes look so much better, they were hooded before and now you can see my eyes are completely a different shape. Then you come to the texture of my skin, and reduction of my pores,' she said Leslie, also accompanied her treatment with a regular aid of supplements Ameri-Vita. 'I'm absolutely going to keep having these treatments,' she assured. 'The results are so good, I can't imagine stopping now.' NeoGen Plasma treatments are available at Dr Martin Kinsella's Re-Enhance clinic in Hale, Cheshire, and also in London. The British star appeared over the moon - after recently opening up about the 2004 incident that changed her life.
The Sun
15-07-2025
- Entertainment
- The Sun
Leslie Ash, 65, reveals the results of her £4,500 non-surgical facelift saying ‘I look ten years younger'
MEN Behaving Badly actress Leslie Ash has undergone a non-surgical facelift. The star, 65, revealed the results of the £4,500 treatment, admitting: 'My friends think I've had a facelift.' 5 5 But Leslie hasn't gone under the knife and instead has been secretly having non-surgical facelift treatments. Over the past eight months, Leslie has had six procedures, known as 'NeoGen Plasma Treatment' with Dr Martin Kinsella. She said: "People keep saying to me, 'What have you done? You look amazing!' "One friend of mine, who shall remain nameless, is convinced I've had surgery because the change was so dramatic, but I can assure you I haven't. "It was really important for me to have a non-invasive treatment that achieves really natural looking results." The actress added: "I'd seen that Shirley Ballas and Linda Lusardi had great results with NeoGen and I know Linda, so it was easy for me to check it out and know that it was a respected treatment with good outcomes." Leslie decided to book in for a consultation after struggling with her visible signs of ageing for a while, which were significantly impacting her self-esteem. 'The difference is really noticeable,' Leslie said after her treatments. 'What's really blown my mind is my jawline, it's so obvious that it has lifted. "And my eyes look so much better, they were hooded before and now you can see my eyes are a completely different shape.' Leslie Ash says horror hospital superbug destroyed her TV career and left her walking with a stick on Good Morning Britain interview She continued: 'Then you come to the texture of my skin, and the reduction of my pores. "My skin feels tighter and more plump, and the overall texture and tone is so much better. "I can definitely say I look like I'm in my mid 50s, so yeah, I'm happy with that, ten years younger.' NeoGen Plasma Treatment works by using ultra-high radio frequency to convert nitrogen gas into nitrogen plasma. A handpiece directs this thermal plasma into the layers of the skin to help control its pre-existing plasma, boosting the skin's natural regenerative mechanism. It's essentially tricking the skin into boosting its levels of collagen and elastin - the two main building blocks of healthy, supple skin. Leslie, who has also been taking daily Ameri-Vita Liver Support drinks, has no plan to call it quits now she's found a treatment that works wonders for her. 'I'm absolutely going to keep having these treatments," she said. "I can't imagine stopping now.' 5
Associated Press
05-07-2025
- Health
- Associated Press
CELFULL Unveils Celfavor NADH Microcapsules: A Breakthrough in Stability That Reshapes the Anti-Aging Industry
CORAL SPRINGS, FL / ACCESS Newswire / July 4, 2025 / CELFULL, a biotechnology company with over 25 years of expertise in anti-aging science, has announced a major breakthrough in longevity innovation: the global launch of Celfavor® NADH Microcapsules, a patented delivery system that resolves the century-long challenge of NADH instability. Journal papers related to NADH This revolutionary technology-protected by seven international invention patents across the U.S., China, Japan, Canada, and South Korea-delivers unprecedented improvements in stability, bioavailability, and targeted delivery, marking a new era in anti-aging therapeutics known as the 'Microcapsule Age.' To accelerate research across the globe, CELFULL has also launched its Global Research Sharing Program, offering free access to the Celfavor® NADH raw material to scientific institutions worldwide. Celfavor®NADH The only effective NADH - Celfavor ® NADH 'The discovery of the therapeutic effect of stabilized NADH is more important to humankind than the discovery of antibiotics.' noted Nobel Laureate Sir John Eccles, underscoring the importance of this innovation. NADH stands for 'nicotinamide adenine dinucleotide (NAD) + hydrogen (H), often dubbed the 'King of Anti-Aging Molecules,' plays a central role in mitochondrial energy production, antioxidant defense, and the activation of longevity proteins. However, its inherent instability-sensitive to heat, light, oxygen, and stomach acid-has severely limited its clinical applications. Conventional NADH degrades by over 70% in one month at room temperature and must be stored at -20°C, making practical use difficult. 7 patents have been certified CELFULL's research team, led by its AI-powered Multi-Target Anti-Aging Institute, spent over a decade solving this problem. The result: Celfavor® NADH Microcapsules, a proprietary technology featuring 250-350μm microcapsules that protect NADH with a multi-core soluble shell made from food-grade materials. In stability tests simulating harsh conditions (40°C / 75% RH), traditional NADH retained only 3.5% of its activity after six months. By contrast, Celfavor® NADH maintained 98.3% activity-demonstrating over 6x shelf-life extension, even without refrigeration or light shielding. The stability of Celfavor® NADH microspheres The Celfavor® NADH Microcapsule system delivers innovation across four dimensions: 1. Enhanced Stability: Microcapsules shield NADH from air, moisture, light, and stomach acid, preserving its full potency in gastrointestinal conditions for up to 4 hours. 2. Targeted Release: Using AI-optimized wall material, the system enables 'zero release in the stomach and sustained release in the intestine.' Simulated intestinal studies show 24-hour continuous release, extending absorption time by 5-8x. 3. Superior Bioavailability: In human trials, a daily dose of 40mg led to a 98% increase in blood NAD⁺ levels, a 3.2x improvement over regular NADH. Performance also surpassed other NAD⁺ precursors like NMN and NR. 4. Formulation Flexibility: Unlike unstable NADH, Celfavor® NADH can be safely co-formulated with vitamins, coenzymes, or peptides in single or multi-ingredient capsules. Celfavor ® NADH microsphere advanced technology surpasses others Celfavor® NADH Microcapsules have been granted seven invention patents and passed all 12 safety evaluations, including cytotoxicity and long-term toxicity tests. It is currently the only NADH raw material globally to pass full-spectrum safety certification. The only globally certified raw material for toxicology and safety experiments 'We are not just creating better products-we are building a platform for the future of longevity,' said Dr. Juliane Hitzel, CEO of CELFULL. 'With this microcapsule technology, we're launching new delivery systems for vitamins, peptides, and more. And by sharing our raw materials with global researchers, we're fostering a collaborative ecosystem that accelerates anti-aging science.' From solving the NADH stability problem to advancing intelligent delivery systems, CELFULL's innovation signals a major milestone in human longevity science. As the Celfavor® NADH Microcapsule technology rolls out globally, the anti-aging industry enters a new chapter-one defined by precision, efficiency, and collaboration. For business cooperation or research partnerships, please contact: [email protected] | Email: [email protected] Website: SOURCE: CELFULL press release
Yahoo
05-07-2025
- Health
- Yahoo
CELFULL Unveils Celfavor NADH Microcapsules: A Breakthrough in Stability That Reshapes the Anti-Aging Industry
CORAL SPRINGS, FL / / July 4, 2025 / CELFULL, a biotechnology company with over 25 years of expertise in anti-aging science, has announced a major breakthrough in longevity innovation: the global launch of Celfavor® NADH Microcapsules, a patented delivery system that resolves the century-long challenge of NADH instability. Journal papers related to NADH This revolutionary technology-protected by seven international invention patents across the U.S., China, Japan, Canada, and South Korea-delivers unprecedented improvements in stability, bioavailability, and targeted delivery, marking a new era in anti-aging therapeutics known as the "Microcapsule Age." To accelerate research across the globe, CELFULL has also launched its Global Research Sharing Program, offering free access to the Celfavor® NADH raw material to scientific institutions worldwide. Celfavor®NADH The only effective NADH - Celfavor ® NADH "The discovery of the therapeutic effect of stabilized NADH is more important to humankind than the discovery of antibiotics." noted Nobel Laureate Sir John Eccles, underscoring the importance of this innovation. NADH stands for "nicotinamide adenine dinucleotide (NAD) + hydrogen (H), often dubbed the "King of Anti-Aging Molecules," plays a central role in mitochondrial energy production, antioxidant defense, and the activation of longevity proteins. However, its inherent instability-sensitive to heat, light, oxygen, and stomach acid-has severely limited its clinical applications. Conventional NADH degrades by over 70% in one month at room temperature and must be stored at -20°C, making practical use difficult. 7 patents have been certified CELFULL's research team, led by its AI-powered Multi-Target Anti-Aging Institute, spent over a decade solving this problem. The result: Celfavor® NADH Microcapsules, a proprietary technology featuring 250-350μm microcapsules that protect NADH with a multi-core soluble shell made from food-grade materials. In stability tests simulating harsh conditions (40°C / 75% RH), traditional NADH retained only 3.5% of its activity after six months. By contrast, Celfavor® NADH maintained 98.3% activity-demonstrating over 6x shelf-life extension, even without refrigeration or light shielding. The stability of Celfavor® NADH microspheres The Celfavor® NADH Microcapsule system delivers innovation across four dimensions: 1. Enhanced Stability: Microcapsules shield NADH from air, moisture, light, and stomach acid, preserving its full potency in gastrointestinal conditions for up to 4 hours. 2. Targeted Release: Using AI-optimized wall material, the system enables "zero release in the stomach and sustained release in the intestine." Simulated intestinal studies show 24-hour continuous release, extending absorption time by 5-8x. 3. Superior Bioavailability: In human trials, a daily dose of 40mg led to a 98% increase in blood NAD⁺ levels, a 3.2x improvement over regular NADH. Performance also surpassed other NAD⁺ precursors like NMN and NR. 4. Formulation Flexibility: Unlike unstable NADH, Celfavor® NADH can be safely co-formulated with vitamins, coenzymes, or peptides in single or multi-ingredient capsules. Celfavor ® NADH microsphere advanced technology surpasses others Celfavor® NADH Microcapsules have been granted seven invention patents and passed all 12 safety evaluations, including cytotoxicity and long-term toxicity tests. It is currently the only NADH raw material globally to pass full-spectrum safety certification. The only globally certified raw material for toxicology and safety experiments "We are not just creating better products-we are building a platform for the future of longevity," said Dr. Juliane Hitzel, CEO of CELFULL. "With this microcapsule technology, we're launching new delivery systems for vitamins, peptides, and more. And by sharing our raw materials with global researchers, we're fostering a collaborative ecosystem that accelerates anti-aging science." From solving the NADH stability problem to advancing intelligent delivery systems, CELFULL's innovation signals a major milestone in human longevity science. As the Celfavor® NADH Microcapsule technology rolls out globally, the anti-aging industry enters a new chapter-one defined by precision, efficiency, and collaboration. For business cooperation or research partnerships, please contact:maggie@ | Email: maggie@ SOURCE: CELFULL View the original press release on ACCESS Newswire Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
25-06-2025
- Health
- Yahoo
Protein Breakthrough Could Extend Healthy Lifespan, Study Finds
A protein called Klotho, when boosted, helps mice live longer and age healthier, offering a potential new path for anti-aging treatments in humans, according to a groundbreaking study from the Universitat Autònoma de Barcelona (UAB). Published in Molecular Therapy and led by Professor Miguel Chillón, the study found that a specific form of Klotho, known as secreted Klotho (s-KL), improved muscle strength, bone health, and brain function in treated mice. These mice lived 15–20% longer than untreated peers, reaching the human equivalent of about 70 years with greater physical and mental vitality. Klotho is known to combat inflammation and oxidative stress, key drivers of aging. Unlike other forms of the protein, s-KL circulates freely in the body without disrupting systems like calcium metabolism, making it a safer candidate for therapies. 'If we can find a viable delivery method, s-KL could make a significant contribution to improving people's quality of life,' the researchers said, per The Brighter Side of News. 'It could help build the healthiest society possible.' Using gene therapy with adeno-associated viruses (AAV9), scientists delivered s-KL through the bloodstream and directly into the brain, targeting areas critical for muscle and memory. Three groups of mice were treated: one at six months (young adulthood), another at 12 months (middle age), and a control group. By 24 months, treated mice showed stronger muscles with larger fibers, less fibrosis, and enhanced repair by satellite cells. Bone structure, particularly in females, remained more intact, suggesting protection against osteoporosis. 'KL treatment improved physical fitness, related to a reduction in muscle fibrosis and an increase in muscular regenerative capacity,' the researchers noted, The Brighter Side reported. In the brain, s-KL promoted new neuron growth in the hippocampus, the memory center, and boosted immune processes like phagocytosis, where cells clear toxic waste. This cleanup is vital as aging glial cells often fail to remove debris, contributing to cognitive decline. Transcriptomic analysis revealed increased gene activity tied to immune response and brain cell regeneration. 'We now have viral vectors that can reach the brain after being administered intravenously, which would make it easier to safely transfer this therapy to humans,' said Joan Roig-Soriano, the study's first author, per The Brighter Side. The findings aim to extend health span — the years spent in good health — rather than just lifespan. The team has filed patents for using Klotho to support cognition, strengthen bones and muscles, and increase longevity. While gene therapy was used in the study, direct protein delivery as a drug is also being explored, though a reliable method to target tissues without side effects is still needed. With global populations aging — experts predict a quarter of people in developed countries will be over 65 by 2060 — such treatments could ease the burden on health systems by preventing age-related diseases before they start. The study's results suggest Klotho could redefine aging, offering a future where decline is not inevitable.
